

Ref. No: 100190521
From: Commercial
Date: 19/05/21
Subject: Fracture Liaison Service provision

REQUEST & RESPONSE

We ask that you please indicate your answer by marking with an “X” next to any answers that apply or by deleting all answers that do not apply. Please avoid answering by italics, underlining or bold, as these do not show up when we process your response.

1. Do your patients over 50 years old have access to a Fracture Liaison Service (FLS)?

b. No commissioned FLS but pathway for bone health management of fracture patients

If you answered ‘no’ (b or c) please move on to question 15.

2. Is your FLS based in secondary care?

a. Yes

b. No

3. For 2019, what percentage of people over 50 with a fracture were offered access to a FLS?

a. (please specify:)

4. For 2019, what percentage of people referred to FLS received an assessment within 12 weeks of fracture diagnosis?

a. (please specify:)

5. For 2019, for those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 16 weeks from fracture?

a. (please specify:)

6. For 2019, For those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 52 weeks from fracture?

a. (please specify:)

7. For 2020, what percentage of people over 50 with a fracture were offered access to a FLS?

a. (please specify:)

8. For 2020, what percentage of people referred to FLS received an assessment within 12 weeks of fracture diagnosis?

a. (please specify:)

9. For 2020, for those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 16 weeks from fracture?

a. (please specify:)

10. For 2020, For those patients receiving osteoporosis drug treatment what percentage were reviewed for follow up 52 weeks from fracture?

a. (please specify:)

11. Is this a permanent service funded by a sustainable source? (e.g., commissioning, health board/trust funded)

a. Yes

b. No

c. partially (please specify:)

12. Do you take part in a national FLS audit? (e.g. FLS-DB)

a. Yes

b. No

13. Please state the name and contact details of the Clinical Lead for this service

a. (please specify)

14. Are there any areas of support you would like further information/support from the ROS? E.g., Clinical Standards, KPIs, Service Improvement / Patient Information etc

a. (please specify:)

For those that answered 'no' to having an FLS (question 1).

15. What are the reasons you do not have an FLS, or access to an FLS for your patients?

a. (please specify:)

This question should be directed to the CCG.

16. Have you tried to establish a FLS previously?

a. See answer 15

17. What has been the barrier/obstacles to implementing a FLS?

a. (Please specify:)

See answer 15

18. If you have not tried to establish a FLS previously, why not?

a. (Please specify)

19. Do you have an osteoporosis service?

a. Yes

20. Do you have a DXA (bone density scanning) service?

a. Yes

21. Please state the name and contact details of the Clinical Leads for osteoporosis, rheumatology or musculo-skeletal, services

a. Q21 – Secondary care Osteoporosis is provided by the Rheumatology department. Musculoskeletal services are provided by local CCGs

Contact details: Julie Dawson CD Rheumatology
Julie.dawson@sthk.nhs.uk
0151 426 1600

22. Are there any areas of support around FLS that you would like further information/support on from the ROS? E.g. patient info, Clinical Standards, KPIs, Service Improvement / Patient Information etc

This question does not fall under the parameters of the FOIA as it is asking for an opinion.